Evidence map›Paper›PMID 26703441›Full record

ArticleArthritis research & therapy2015

Soluble biglycan: a potential mediator of cartilage degradation in osteoarthritis.

Goncalo Barreto, Antti Soininen, Pekka Ylinen, Jerker Sandelin, Yrjö T Konttinen, Dan C Nordström, Kari K Eklund

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. NOS inhibition reverses TLR2-induced chondrocyte dysfunction and attenuates age-related osteoarthritis.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  11. Review
  12. Salivary biglycan-neo-epitope-BGNOsteoarthritis and cartilage open · 2023
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Goncalo BarretoDepartment of Internal Medicine and Rehabilitation, University of Helsinki and Helsinki University (Central) Hospital, Biomedicum 1, PO Box 63, FIN-00290, Helsinki, Finland. goncalo.barreto@helsinki.fi.
Antti SoininenORTON Orthopaedic Hospital, Helsinki, Finland. antti.soininen@orton.fi.
Pekka YlinenORTON Orthopaedic Hospital, Helsinki, Finland. pekka.ylinen@orton.fi.
Jerker SandelinORTON Orthopaedic Hospital, Helsinki, Finland. jerker.sandelin@orton.fi.
Yrjö T KonttinenDepartment of Internal Medicine and Rehabilitation, University of Helsinki and Helsinki University (Central) Hospital, Biomedicum 1, PO Box 63, FIN-00290, Helsinki, Finland.
Dan C NordströmDepartment of Internal Medicine and Rehabilitation, University of Helsinki and Helsinki University (Central) Hospital, Biomedicum 1, PO Box 63, FIN-00290, Helsinki, Finland. dan.norsdtrom@hus.fi.
Kari K EklundDepartment of Rheumatology, University of Helsinki and Helsinki University (Central) Hospital, Helsinki, Finland. kari.eklund@hus.fi.
Invalidisäätiö · FIUniversity of Helsinki · FIHelsinki University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSoluble biglycan (sBGN) and soluble decorin (sDCN), are two closely related essential components of extracellular matrix which both have been shown to possess proinflammatory properties. We studied whether sBGN or sDCN were present in synovial fluid (SF) of osteoarthritis (OA) or rheumatoid arthritis (RA) patients and studied sBGN or sDCN potential role in the degradation of OA cartilage.

methodsSF obtained from meniscus tear, OA, and RA patients were analysed for sBGN and sDCN using enzyme-linked immunosorbent assays. OA chondrocytes and cartilage explants were stimulated for 48 h with 5 μg/ml sBGN or 1 μg/ml lipopolysaccharide. Messenger RNA (mRNA) levels of Toll-like receptors (TLRs), proteinases and cartilage matrix molecules were determined using quantitative real-time polymerase chain reaction. Protein levels of matrix metalloproteinases (MMPs) and cytokines were measured using Luminex xMap technology. Production of nitric oxide (NO), release of proteoglycans and soluble collagen were measured from conditioned culture media using biochemical assays. OA cartilage explant proteoglycans were stained for Safranin O and quantified using image analysis. TLR4 activation by sBGN and sDCN was studied in engineered HEK-293 cells with TLR4 signalling genes inserted together with a reporter gene.

resultssBGN was found in meniscus tear SF (14 ± 2 ng/ml), OA SF (582 ± 307 ng/ml) and RA SF (1191 ± 482 ng/ml). Low levels of sDCN could also be detected in SF of meniscus tear (51 ± 4) ng/ml, OA (52 ± 3 ng/ml), and RA (49 ± 4 ng/ml). Stimulation of chondrocytes with sBGN increased significantly the mRNA and protein expression of catabolic MMPs, including MMP1, MMP9 and MMP13, and of inflammatory cytokines interleukin (IL)-6 and IL-8, whereas the expression of anabolic markers aggrecan and collagen type II was decreased. sBGN induced release of proteoglycans, collagen and NO from chondrocytes and cartilage explants. The catabolic response in explants was dependent of OA cartilage degradation stage. The mechanism of action of sBGN was mainly mediated through the TLR4-nuclear factor-κB pathway.

conclusionsHigh levels of sBGN was found in advanced OA and RA SF. sBGN activates chondrocytes mainly via TLR4, which results in net loss of cartilage. Thus, sBGN can be a mediator of OA cartilage degradation and also a potential biomarker for arthritis.

Indexed as

AgedArthritis, RheumatoidBiglycanBiomarkersCartilage, ArticularEnzyme-Linked Immunosorbent AssayFemaleHEK293 CellsHumansMaleMiddle AgedOsteoarthritis, KneeReal-Time Polymerase Chain ReactionSynovial FluidBGN protein, humanBiglycanBiomarkers

Identifiers

PMID26703441
PMCPMC4718039
OpenAlexW2211584449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.